Home > Haematology > EHA 2021 > Myeloma and Myelofibrosis > Novel targets in myelofibrosis: overview of emergent therapies

Novel targets in myelofibrosis: overview of emergent therapies

Presented By
Prof. Francesco Passamonti, University of Insubria, Italy
EHA 2021
Several late-stage clinical trials have shown encouraging results for novel therapies for myelofibrosis in at least a subset of patient populations. The novel agents, including pacritinib, momelotinib, parsaclisib, KRT-232, and tagraxofusp, are directed at a variety of targets. Prof. Francesco Passamonti (University of Insubria, Italy) gave an overview of the evolving therapeutic landscape of myelofibrosis, which is moving beyond ruxolitinib alone [1]. Different pathways can be used to modify myelofibrosis: signal transduction inhibitors such as JAK inhibitors, apoptotic pathway enhancers, epigenetic modifiers, agents harnessing host immunity, and agents affecting DNA replication [2]. The JAK2 inhibitor pacritinib was tested in phase 3 clinical studies (PERSIST-1 [NCT01773187]; PERSIST-2 [

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on